GlassScriptPhysician profile
Ajaz M Khan
NPI 1043484736
$6,995.97
in general payments reported to CMS, 2019-2025
15 companies · $4,382 in 2025
The $4,382 reported for 2025 was more than what 80% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $111 · 2022: $418 · 2023: $194 · 2024: $1,892 · 2025: $4,382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,780 · Food and Beverage: $687.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,780.00 |
| Food and Beverage | $687.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,357.85 | 2023-2025 | Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $1,785.00 | 2025 | Alunbrig |
| Fennec Pharmaceuticals, INC. | $1,715.23 | 2024-2025 | Pedmark, Fyarro |
| Foundation Medicine, INC. | $229.00 | 2022 | |
| Lilly USA, LLC | $154.19 | 2023 | Mounjaro |
| Clovis Oncology, INC. | $153.78 | 2022 | |
| Janssen Research & Development, LLC | $150.00 | 2025 | |
| Novartis Pharmaceuticals Corporation | $136.44 | 2024 | |
| Amgen INC. | $99.00 | 2021 | |
| Gilead Sciences, INC. | $68.16 | 2021-2025 | Trodelvy |
| Daiichi Sankyo INC. | $50.58 | 2024-2025 | Enhertu |
| Jazz Pharmaceuticals INC. | $35.06 | 2022 | |
| Springworks Therapeutics, INC. | $34.75 | 2024 | Ogsiveo |
| Deciphera Pharmaceuticals INC. | $26.93 | 2023 | Qinlock |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ajaz Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.